Phathom Pharmaceuticals (PHAT) Stock Chart & Stock Price History $6.69 +0.27 (+4.21%) Closing price 03/27/2025 04:00 PM EasternExtended Trading$6.20 -0.49 (-7.25%) As of 03/27/2025 07:25 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Chart Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Phathom Pharmaceuticals Stock Price Performance 5 Day Performance+7.38%1 Month Performance+21.20%3 Month Performance-18.22%6 Month Performance-61.82%Year-To-Date Performance-17.61%1 Year Performance-37.01% Receive PHAT Stock News and Ratings via EmailSign-up to receive the latest news and ratings for Phathom Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address PHAT Stock Chart for Friday, March, 28, 2025 PHAT Chart by TradingViewRemove Ads Phathom Pharmaceuticals Stock Price History Daily Weekly Monthly Time Frame Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year Time Frame * Start Date * End Date Export to Excel DateOpening PriceClosing PriceHighLowVolumeMarket Capitalization03/27/2025$6.42$6.69+4.21%$6.74$6.34679,819 shs$465.87 million03/26/2025$6.39$6.42+0.47%$6.51$6.031.12 million shs$447.07 million03/25/2025$6.55$6.39-2.44%$6.52$6.16797,322 shs$444.98 million03/24/2025$6.23$6.55+5.14%$6.61$6.13874,191 shs$456.12 million03/21/2025$6.26$6.23-0.48%$6.54$6.061.52 million shs$433.84 million03/20/2025$6.08$6.26+2.96%$6.31$5.921.80 million shs$435.93 million03/19/2025$5.54$6.08+9.75%$6.16$5.471.65 million shs$423.39 million03/18/2025$4.84$5.54+14.46%$5.85$4.982.40 million shs$385.79 million03/17/2025$4.41$4.84+9.75%$4.89$4.40921,893 shs$337.04 million03/14/2025$4.22$4.41+4.50%$4.48$4.071.24 million shs$301.54 million Get the Latest News and Ratings for PHAT and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Phathom Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. 03/13/2025$5.00$4.22-15.60%$5.05$4.191.42 million shs$288.55 million03/12/2025$4.79$5.00+4.38%$5.25$4.621.53 million shs$341.89 million03/11/2025$4.40$4.79+8.86%$4.85$4.321.59 million shs$327.53 million03/10/2025$5.06$4.40-13.04%$5.07$4.341.82 million shs$300.86 million03/07/2025$5.90$5.06-14.24%$5.77$5.021.81 million shs$345.99 million03/06/2025$6.08$5.90-2.96%$6.98$5.352.35 million shs$403.42 million03/05/2025$5.58$6.08+8.96%$6.21$5.641.03 million shs$415.73 million03/04/2025$5.21$5.58+7.10%$5.61$5.07863,055 shs$381.54 million03/03/2025$5.52$5.21-5.62%$5.91$5.151.05 million shs$356.24 million02/28/2025$5.76$5.52-4.17%$5.74$5.36946,894 shs$377.44 million02/27/2025$5.79$5.76-0.52%$5.87$5.62664,357 shs$393.85 million Related Companies Amphastar Pharmaceuticals Stock Price Chart Ardelyx Stock Price Chart Evotec Stock Price Chart 89bio Stock Price Chart Ocular Therapeutix Stock Price Chart Structure Therapeutics Stock Price Chart Iovance Biotherapeutics Stock Price Chart Calliditas Therapeutics AB (publ) Stock Price Chart Aurinia Pharmaceuticals Stock Price Chart Gyre Therapeutics Stock Price Chart Receive PHAT Stock News and Ratings via EmailSign-up to receive the latest news and ratings for Phathom Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. This page (NASDAQ:PHAT) was last updated on 3/28/2025 by MarketBeat.com Staff From Our PartnersA $6.9 Trillion Cash Tsunami Is Coming – Move Your Money NOWExpert: "Prepare For the Mother of All Melt-Ups" In the wake of Wall Street volatility, stock-picking legen...Stansberry Research | SponsoredElon Warns: Exec Order 14024 Targets DollarExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredTrump Makes Major Crypto AnnouncementTrump Ends the “War on Crypto” I expect it to pump the market, which is why I'm recommending ONE coin to al...Crypto 101 Media | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Phathom Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Phathom Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
